Like remoras hitching a ride on a shark, private businesses are capitalizing on President Trump’s AI-aggressive trip to the Middle East. 

Citing evidence from documents and interviews, the Guardian released an exposé accusing UnitedHealth of directly influencing the day-to-day operations of some 2,000 nursing homes, resulting in patients not receiving necessary emergency care.

Here’s a big thing to watch for in the wake of the President’s flashy Middle East tour: the AI “acceleration partnership” between the U.S. and the United Arab Emirates. 

John Simon, MD, is a big advocate for these elective exams, but the American College of Radiology and some members of the specialty oppose this practice. 

The deals account for most of Rite Aid’s remaining stores, as the bankrupt chain nears its final days.

KFF Health News interviewed multiple independent pharmacies for a new report, detailing their basements full of generic and specialty drugs as a hedge against supply shocks. 

According to a report, Walgreens also expressed interest in an unknown number of pharmacies as Rite Aid seeks to liquidate all its assets.

Why do investors equate these companies with beautiful, mythical beasts? Because startups with such dazzling attributes are—or long were—rarely seen.